Loading clinical trials...
Loading clinical trials...
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy
Conditions
Interventions
Rociletinib
Pemetrexed or gemcitabine or paclitaxel or docetaxel
Locations
80
United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
City of Hope Cancer Center
Duarte, California, United States
Saint Joseph Heritage Healthcare
Fullerton, California, United States
University of California San Diego Moores Cancer Center
La Jolla, California, United States
Cancer Care Associates Medical Group, Inc.
Redondo Beach, California, United States
Sutter Cancer Center
Sacramento, California, United States
Start Date
February 1, 2015
Primary Completion Date
March 29, 2018
Completion Date
March 29, 2018
Last Updated
August 14, 2019
NCT06758401
NCT07431827
NCT06427941
NCT06476808
NCT05142189
NCT07164313
Lead Sponsor
Clovis Oncology, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions